| GEM-CLARIDEX: Ld vs BiRd (NCT02575144) | PETHEMA Foundation | 2015-09-01 |
| NMP in Relapsed / Refractory Myeloma (NCT02468687) | Peter MacCallum Cancer Centre, Australia | 2015-08-20 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment. (NCT02797041) | IRCCS Centro di Riferimento Oncologico della Basilicata | 2015-08-01 |
| Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma (NCT02412228) | John L. Reagan | 2015-08-01 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) (NCT02440464) | National Heart, Lung, and Blood Institute (NHLBI) | 2015-08-01 |
| Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma (NCT02519114) | Maastricht University Medical Center | 2015-08-01 |
| A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) (NCT02431208) | Hoffmann-La Roche | 2015-07-22 |
| Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients (NCT02420223) | Medical College of Wisconsin | 2015-07-17 |
| A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma (NCT02497378) | Janssen Pharmaceutical K.K. | 2015-07-10 |
| Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients (NCT02514239) | Boehringer Ingelheim | 2015-07-08 |
| Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients (NCT02389543) | Karyopharm Therapeutics Inc | 2015-07-01 |
| iCare for Cancer Patients (NCT02435550) | University of Florida | 2015-06-26 |
| Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma (NCT02537808) | iOMEDICO AG | 2015-06-23 |
| Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma (NCT02315716) | University College, London | 2015-06-16 |
| Umbilical Cord Blood Transplantation From Unrelated Donors (NCT03016806) | University of Rochester | 2015-06-01 |
| Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure (NCT04045561) | Centre Hospitalier Universitaire de Nīmes | 2015-06-01 |
| MMRF Molecular Profiling Protocol (NCT02884102) | Multiple Myeloma Research Foundation | 2015-06-01 |
| A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (NCT02495922) | University of Heidelberg Medical Center | 2015-06-01 |
| Improving the Quality of Multiple Myeloma Treatment With Patient Care Plans (NCT03046329) | Carevive Systems, Inc. | 2015-06-01 |
| Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies (NCT02997813) | Intergroupe Francophone du Myelome | 2015-06-01 |
| Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma (NCT02331368) | University of Michigan Rogel Cancer Center | 2015-06-01 |
| Selinexor Treatment of Refractory Myeloma (NCT02336815) | Karyopharm Therapeutics Inc | 2015-05-26 |
| A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma (NCT02316106) | Janssen Research & Development, LLC | 2015-05-20 |
| Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma (NCT02400242) | Celgene | 2015-05-07 |
| Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM (NCT02375555) | Dana-Farber Cancer Institute | 2015-05-07 |
| Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma (NCT02462525) | AbbVie | 2015-05-06 |
| A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma (NCT02402725) | Boston Medical Center | 2015-05-01 |
| Exercise in Patients With Multiple Myeloma (NCT02439112) | Zealand University Hospital | 2015-05-01 |
| Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma (NCT02335983) | Amgen | 2015-04-30 |
| A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg (NCT02921828) | Celgene | 2015-04-30 |
| High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma (NCT02416206) | Northside Hospital, Inc. | 2015-04-27 |
| Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer (NCT02260414) | Centre Hospitalier Universitaire de Saint Etienne | 2015-04-14 |
| A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer (NCT02391480) | AbbVie | 2015-04-14 |
| Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma (NCT02275403) | The Christie NHS Foundation Trust | 2015-04-13 |
| A Study of VLX1570 and Dexamethasone in Myeloma Patients (NCT02372240) | Vivolux AB | 2015-04-08 |
| CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma (NCT02362165) | Sun Yat-sen University | 2015-04-01 |
| T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650) | Shenzhen Second People's Hospital | 2015-04-01 |
| Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (NCT02291848) | Baylor College of Medicine | 2015-04-01 |
| An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice (NCT02902900) | Celgene | 2015-04-01 |
| Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT02410694) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2015-04-01 |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (NCT02203825) | Celyad Oncology SA | 2015-03-01 |
| UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus (NCT02192775) | University of Arkansas | 2015-03-01 |
| Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) (NCT02322320) | National Heart, Lung, and Blood Institute (NHLBI) | 2015-03-01 |
| UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib (NCT02140840) | University of Arkansas | 2015-03-01 |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) (NCT02393248) | Incyte Corporation | 2015-02-27 |
| Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma (NCT02220608) | Washington University School of Medicine | 2015-02-20 |
| Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice (NCT02555839) | Celgene | 2015-02-20 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (NCT02362035) | Acerta Pharma BV | 2015-02-20 |
| Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan (NCT02272803) | Bristol-Myers Squibb | 2015-02-20 |
| Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy (NCT02358980) | Azienda USL Reggio Emilia - IRCCS | 2015-02-18 |
| Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma (NCT02252172) | Janssen Research & Development, LLC | 2015-02-16 |
| Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease (NCT02158052) | Massachusetts General Hospital | 2015-02-01 |
| Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma (NCT02274519) | Mayo Clinic | 2015-02-01 |
| PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients (NCT02104427) | GPCR Therapeutics, Inc. | 2015-02-01 |
| Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma (NCT02278315) | Cellectar Biosciences, Inc. | 2015-02-01 |
| Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma (NCT02332850) | Thomas Martin, MD | 2015-01-21 |
| Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma (NCT02253316) | Washington University School of Medicine | 2015-01-20 |
| A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation (NCT02112045) | Washington University School of Medicine | 2015-01-20 |
| Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma (NCT02254551) | SCRI Development Innovations, LLC | 2015-01-01 |
| "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab " (NCT02419118) | Vejle Hospital | 2015-01-01 |
| Prolonged Protection From Bone Disease in Multiple Myeloma (NCT02286830) | Thomas Lund | 2015-01-01 |
| Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support (NCT02572492) | Henrik Gregersen | 2015-01-01 |
| Clarithromycin in Multiple Myeloma Induction Therapy (NCT02573935) | Henrik Gregersen | 2015-01-01 |
| Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma (NCT02197221) | University Hospital, Toulouse | 2015-01-01 |
| Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma (NCT02861287) | Institut Paoli-Calmettes | 2015-01-01 |
| 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma (NCT02289222) | Ashraf Badros | 2014-12-30 |
| Study of the Immune Response After Vaccination in Multiple Myeloma Patients (NCT02294487) | Wake Forest University Health Sciences | 2014-12-30 |
| A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma (NCT02195479) | Janssen Research & Development, LLC | 2014-12-09 |
| A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma (NCT02252263) | Bristol-Myers Squibb | 2014-12-09 |
| Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib (NCT02294357) | Oncotherapeutics | 2014-12-01 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma (NCT02219178) | Cancer Trials Ireland | 2014-11-01 |
| Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib (NCT02158702) | National University Hospital, Singapore | 2014-11-01 |
| Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients (NCT02308280) | Maisonneuve-Rosemont Hospital | 2014-11-01 |
| Optimising Renal Outcome in Myeloma Renal Failure (NCT02424851) | Oxford University Hospitals NHS Trust | 2014-11-01 |
| Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma (NCT02237261) | University Hospital Heidelberg | 2014-11-01 |
| Prospective Observation of Cardiac Safety With Proteasome Inhibition (NCT02178579) | Vanderbilt University Medical Center | 2014-11-01 |
| Blood Samples to Identify Biomarkers of Busulfan (NCT02291965) | Fred Hutchinson Cancer Center | 2014-11-01 |
| Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients (NCT02471820) | Meletios A. Dimopoulos | 2014-11-01 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant (NCT01930162) | Novartis Pharmaceuticals | 2014-10-07 |
| Role of Osteocytes in Myeloma Bone Disease (NCT02212262) | Attaya Suvannasankha | 2014-10-07 |
| A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma (NCT02230917) | Rebecca Silbermann | 2014-10-01 |
| Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma (NCT02221479) | Genzyme, a Sanofi Company | 2014-10-01 |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT02240719) | University of California, Davis | 2014-10-01 |
| Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma (NCT02217163) | Singapore General Hospital | 2014-10-01 |
| Myeloma Treatment in Real Life (NCT03638232) | University Hospital, Toulouse | 2014-10-01 |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma (NCT02189343) | Celgene | 2014-09-15 |
| Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma (NCT02168101) | SCRI Development Innovations, LLC | 2014-09-01 |
| Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies (NCT02160951) | Novartis Pharmaceuticals | 2014-09-01 |
| Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (NCT02098109) | Washington University School of Medicine | 2014-08-20 |
| B-Cell Hematologic Malignancy Vaccination Registry (NCT02298816) | Wake Forest University Health Sciences | 2014-08-01 |
| A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma (NCT01999335) | Amgen | 2014-07-30 |
| Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 (NCT02064387) | GlaxoSmithKline | 2014-07-29 |
| A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (NCT02076009) | Janssen Research & Development, LLC | 2014-07-23 |
| A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant (NCT02181413) | Takeda | 2014-07-16 |
| Nonmyeloablative Haploidentical Transplant Followed by MLN9708 (NCT02169791) | Northside Hospital, Inc. | 2014-07-15 |
| A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma (NCT02157636) | Constellation Pharmaceuticals | 2014-07-15 |
| Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients (NCT02188368) | Oncotherapeutics | 2014-07-07 |